Core Viewpoint - The report from CITIC Securities indicates that medical AI will accelerate the restructuring of the trillion-dollar pharmaceutical market, with a fundamental change in the logic of AI healthcare expected by 2026 due to clearer and stronger payment sources this year [1] Summary by Categories AI Healthcare Commercialization - 2026 is anticipated to be a year with stronger certainty in the commercialization of AI healthcare, opening up more opportunities for business in this sector [1] Key Focus Areas - The report suggests focusing on five main areas: AI pharmaceuticals, grassroots AI healthcare applications, medical data circulation and trading, AI pathology diagnosis, AI medical models, and C-end expansion channels [1]

Core Insights - The report from CITIC Securities indicates that medical AI will accelerate the restructuring of the trillion-dollar pharmaceutical market [1] - It is believed that by 2026, the logic of AI in healthcare will undergo fundamental changes, primarily due to clearer and stronger payment capabilities this year [1] - 2026 is expected to be a year with stronger certainty in the commercialization of AI in healthcare, opening up more opportunities for its commercialization [1] Key Focus Areas - The report suggests focusing on five main areas: AI pharmaceuticals, grassroots AI healthcare applications, medical data circulation and trading, AI pathology diagnosis, AI healthcare models, and C-end expansion channels [1]

Group 1 - The year 2025 is significant for China's innovative drug exports, with a total transaction amount reaching $135.655 billion, a down payment of $7 billion, and a record 157 transactions [1] - The innovative drug sector not only provides R&D funding for companies but also reshapes the industry's valuation system, with the innovative drug index increasing by 35.31%, outperforming the CSI 300 index by 17.65% [1] - Breakthroughs in small nucleic acid drugs have been noted, with GSK's Bepirovirsen for chronic hepatitis B completing Phase III studies, and domestic companies like Yuyuan Pharmaceutical and Reborn Biotech making significant progress in liver-targeted drug development [1] Group 2 - In the oral autoimmune drug sector, Takeda's TYK2 inhibitor zasocitinib shows excellent performance in Phase III studies for psoriasis, with domestic companies such as Yifang Biotech and Nocare Biopharma also advancing related clinical trials [1] - Brain-computer interface technology is entering the industrialization phase, with Neuralink planning to mass-produce devices by 2026, supported by domestic policies accelerating medical application implementation [1] - The ZAP-X radiation therapy device brings new breakthroughs in brain tumor treatment, with domestic market demand potential reaching a scale of hundreds of billions [1] Group 3 - The commercialization path for AI in healthcare is becoming clearer, with pathology fee reforms establishing pricing mechanisms for AI-assisted diagnosis, leading to accelerated development in consumer applications [1]